BCL2 and neoplasm: Similarly, a previous study reported that combinatorial therapy of CD19.CAR-T cells with ABT737, a multi-target inhibitor blocking Bcl-2, Bcl-xl and Bcl-w, showed a better anti-tumor activity than either tested individually (39).